Response to “Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped” - The Role ofCYP3A4andCYP3A5Polymorphisms in Clinical Pharmacokinetics of Voriconazole
T J Walsh; B Moriyama; S R Penzak; T E Klein; K E Caudle
Author Information: Transplantation-Oncology Infectious Diseases Program, Departments of Medicine, Pediatrics, and Microbiology and Infectious Diseases, Weill Cornell Medical Center of Cornell University, New York, New York, USA
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.